MX2023002024A - Métodos de tratamiento con modulador de miosina. - Google Patents
Métodos de tratamiento con modulador de miosina.Info
- Publication number
- MX2023002024A MX2023002024A MX2023002024A MX2023002024A MX2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- disclosed
- myosin
- modulator
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 102000003505 Myosin Human genes 0.000 title abstract 2
- 108060008487 Myosin Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002876 beta blocker Substances 0.000 abstract 2
- 229940097320 beta blocking agent Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072094P | 2020-08-28 | 2020-08-28 | |
| PCT/US2021/047711 WO2022047004A1 (en) | 2020-08-28 | 2021-08-26 | Methods of treatment with myosin modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002024A true MX2023002024A (es) | 2023-05-10 |
Family
ID=80355673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002024A MX2023002024A (es) | 2020-08-28 | 2021-08-26 | Métodos de tratamiento con modulador de miosina. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4203927A4 (https=) |
| JP (1) | JP2023540485A (https=) |
| KR (1) | KR20230079053A (https=) |
| CN (1) | CN116490185A (https=) |
| AU (1) | AU2021334316A1 (https=) |
| CA (1) | CA3190060A1 (https=) |
| IL (1) | IL300775A (https=) |
| MX (1) | MX2023002024A (https=) |
| WO (1) | WO2022047004A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| US20250152094A1 (en) | 2022-01-05 | 2025-05-15 | Prolaio, Inc. | System and method for monitoring an efficacy of a treatment for a cardiac condition |
| EP4514355A1 (en) * | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| CN120187352A (zh) * | 2022-10-21 | 2025-06-20 | 普若莱奥公司 | 治疗肥厚型心肌病的系统和方法 |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| CA3071948A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) * | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| EA202191152A1 (ru) * | 2018-10-29 | 2022-01-19 | Миокардиа, Инк. | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона |
| CN111116492B (zh) * | 2019-01-25 | 2021-07-09 | 青岛吉澳医药科技有限公司 | 氘代苯甲氨嘧啶二酮衍生物及其用途 |
| WO2020257609A1 (en) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| EP4054588A4 (en) * | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
-
2021
- 2021-08-26 MX MX2023002024A patent/MX2023002024A/es unknown
- 2021-08-26 CN CN202180070780.5A patent/CN116490185A/zh active Pending
- 2021-08-26 KR KR1020237009983A patent/KR20230079053A/ko active Pending
- 2021-08-26 CA CA3190060A patent/CA3190060A1/en active Pending
- 2021-08-26 IL IL300775A patent/IL300775A/en unknown
- 2021-08-26 JP JP2023513628A patent/JP2023540485A/ja active Pending
- 2021-08-26 AU AU2021334316A patent/AU2021334316A1/en active Pending
- 2021-08-26 WO PCT/US2021/047711 patent/WO2022047004A1/en not_active Ceased
- 2021-08-26 EP EP21862716.4A patent/EP4203927A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490185A (zh) | 2023-07-25 |
| AU2021334316A9 (en) | 2024-08-01 |
| EP4203927A4 (en) | 2024-09-04 |
| WO2022047004A1 (en) | 2022-03-03 |
| EP4203927A1 (en) | 2023-07-05 |
| IL300775A (en) | 2023-04-01 |
| KR20230079053A (ko) | 2023-06-05 |
| CA3190060A1 (en) | 2022-03-03 |
| US20240299390A1 (en) | 2024-09-12 |
| AU2021334316A1 (en) | 2023-05-04 |
| JP2023540485A (ja) | 2023-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
| MX2022005465A (es) | Metodos de tratamiento con modulador de miosina. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| EP4706638A3 (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| MX2023001717A (es) | Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer. | |
| MX2024011142A (es) | Tratamiento de neurofibromas cutaneos con mirdametinib. | |
| MY209833A (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| BR112022025920A2 (pt) | Tratamento de artrite reumatoide | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| WO2023196584A3 (en) | Endocytosis inhibitors and their use for pain treatment | |
| WO2021011844A3 (en) | Combination cancer therapy agents and methods | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| WO2022026092A3 (en) | Method of treatment of neutrophil-driven inflammatory pathologies | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| ZA202201446B (en) | Methods of treating multifocal cancer |